Clinical Assessment Scales* | Screening and Baseline | Treatment Course 1 | Follow-up Period 1 | Â | Treatment Course 2 | Follow-up Period 2 | ||||
---|---|---|---|---|---|---|---|---|---|---|
 | Week 0 | Visit 1,2, 3,4 | Visit 5 | Week 1 | Week 4 | Visit 1,2, 3,4 | Visit 5 | Week 1 | Week 4 | |
MINI | X | Â | Â | Â | Â | Â | Â | Â | Â | |
TASS | X | Â | Â | Â | Â | Â | Â | Â | Â | |
GAD-7 | X | Â | X | X | X | Â | X | X | X | |
PHQ-9 | X | Â | Â | Â | Â | Â | Â | Â | Â | |
SSI | X | Â | X | X | X | Â | X | X | X | |
HRSD-17 | X | Â | X | X | X | Â | X | X | X | |
HRSD-6 | X | Â | X | X | X | Â | X | X | X | |
ATHF | X | Â | Â | Â | Â | Â | Â | Â | Â | |
BDI-II | X | X | X | X | X | X | X | Â | X | |
Side effect report | X | X | X | X | X | X | X | X | X | |
Reproductive history (females only) | X | Â | Â | Â | Â | X (prior to Visit 1 only) | Â | Â | Â | |
Substance Use Questions | X | X | X | Â | Â | X | X | Â | Â | |
Stanford Expectancy Questionnaire | X | Â | Â | Â | Â | X (prior to Visit 1 only) | Â | Â | Â | |
HCS | Â | Â | Â | X | Â | Â | Â | X | Â | |
Group Assignment (participants and technicians) | Â | X (after visit 1) | Â | X | X | Â | Â | Â | Â |